{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:57:22Z","timestamp":1790873842627,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006181","name":"Fundacao de Amparo a Pesquisa do Estado da Bahia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006181","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jad.2023.02.151","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T20:23:27Z","timestamp":1677875007000},"page":"7-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study"],"prefix":"10.1016","volume":"330","author":[{"given":"Gustavo C.","family":"Leal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breno","family":"Souza-Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo P.","family":"Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor D.","family":"Bandeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Teresa","family":"Caliman-Fontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz A.","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Faria-Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00edvia N.F.","family":"Guerreiro-Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Jesus-Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha S.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Lins-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana A.","family":"Fontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00edza","family":"Alves-Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidelcina","family":"Rugieri-Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e1ssio","family":"Santos-Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda S.","family":"Correia-Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Sanacora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Acioly L.T.","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas C.","family":"Quarantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2023.02.151_bb0005","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1590\/S1516-44462000000300003","article-title":"Mini International Neuropsychiatric Interview (MINI): valida\u00e7\u00e3o de entrevista breve para diagn\u00f3stico de transtornos mentais","volume":"22","author":"Amorim","year":"2000","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.jad.2023.02.151_bb0010","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"278","author":"Bahji","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.02.151_bb5000","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2023.02.151_bb0015","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability","volume":"26","author":"Bonaventura","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2023.02.151_bb0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1024465317902","article-title":"Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)","volume":"11","author":"Bremner","year":"1998","journal-title":"J. Trauma. Stress."},{"key":"10.1016\/j.jad.2023.02.151_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011612.pub2","article-title":"Ketamine and other glutamate receptor modulators for depression in adults","author":"Caddy","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jad.2023.02.151_bb0030","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","volume":"175","author":"Canuso","year":"2018","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jad.2023.02.151_bb0035","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/da.22774","article-title":"Finding factors that predict treatment-resistant depression: results of a cohort study","volume":"35","author":"Cepeda","year":"2018","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2023.02.151_bb0040","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pbb.2019.04.008","article-title":"Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine","volume":"181","author":"Chang","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.jad.2023.02.151_bb0045","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41380-022-01447-4","article-title":"Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al.","volume":"27","author":"Chen","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2023.02.151_bb0050","first-page":"244","article-title":"Validity and reliability of the Observer\u2019s Assessment of Alertness\/Sedation Scale: study with intravenous midazolam","volume":"10","author":"Chernik","year":"1990","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.02.151_bb0055","first-page":"1","article-title":"Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study","volume":"264","author":"Correia-Melo","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.02.151_bb0060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2023.02.151_bb0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(97)01116-3","article-title":"Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord","volume":"333","author":"Ebert","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jad.2023.02.151_bb0070","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression\u202f: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2023.02.151_bb0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.116.239228","article-title":"Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine","volume":"361","author":"Fukumoto","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jad.2023.02.151_bb0080","article-title":"ECDEU Assessment Manual for Psychopharmacology: Revised","author":"Guy","year":"1976"},{"key":"10.1016\/j.jad.2023.02.151_bb0085","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.25531","article-title":"Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis","volume":"4","author":"Jones","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jad.2023.02.151_bb0090","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/acps.12959","article-title":"Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study","volume":"139","author":"Kautzky","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2023.02.151_bb0095","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.npp.1300059","article-title":"Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administraton summary basis of approval reports","volume":"28","author":"Khan","year":"2003","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.jad.2023.02.151_bb0100","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2023.02.151_bb0105","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2023.02.151_bb0110","article-title":"Intravenous arketamine for treatment-resistant depression: open-label pilot study","author":"Leal","year":"2020","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2023.02.151_bb0115","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0304-3959(94)00170-J","article-title":"Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain","volume":"61","author":"Mathisen","year":"1995","journal-title":"Pain"},{"key":"10.1016\/j.jad.2023.02.151_bb0120","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1017\/S0033291714001603","article-title":"A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes","volume":"45","author":"McGirr","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2023.02.151_bb0125","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.02.151_bb0130","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/2045125316631267","article-title":"Ketamine enantiomers in the rapid and sustained antidepressant effects","volume":"6","author":"Muller","year":"2016","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.02.151_bb0135","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2023.02.151_bb0140","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0022-3565(25)11430-4","article-title":"Effects of ketamine on sensory perception: evidence for a role of N-methyl-d-aspartate receptors","volume":"260","author":"Oye","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jad.2023.02.151_bb0145","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","article-title":"Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial","volume":"176","author":"Phillips","year":"2019","journal-title":"AJP"},{"key":"10.1016\/j.jad.2023.02.151_bb0150","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.02.151_bb0155","doi-asserted-by":"crossref","unstructured":"Popova, V., Daly, E.J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M.E., Shelton, R.C., Molero, P., Vieta, E., Bajbouj, M., Manji, H., Drevets, W.C., Singh, J.B., n.d. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am. J. Psychiatry. doi:https:\/\/doi.org\/10.1176\/appi.ajp.2019.19020172.","DOI":"10.1176\/appi.ajp.2019.19020172"},{"key":"10.1016\/j.jad.2023.02.151_bb0160","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2022"},{"key":"10.1016\/j.jad.2023.02.151_bb0165","first-page":"43","article-title":"Tradu\u00e7ao e adapta\u00e7ao de um instrumento de avalia\u00e7ao psicopatol\u00f3gica das psicoses: a Escala breve de avalia\u00e7ao psiqui\u00e1trica-versao ancorada (BPRS-A)","author":"Romano","year":"1996","journal-title":"J. Bras. Psiquiatr"},{"key":"10.1016\/j.jad.2023.02.151_bb0170","series-title":"Textbook of Intravenous Anesthesia","first-page":"171","article-title":"Ketamine and its isomers","author":"Schuettler","year":"1997"},{"key":"10.1016\/j.jad.2023.02.151_bb0175","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2023.02.151_bb0180","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"AJP"},{"key":"10.1016\/j.jad.2023.02.151_bb0185","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.4088\/JCP.v68n0713","article-title":"Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study","volume":"68","author":"Souery","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.02.151_bb0190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0924-977X(96)00042-9","article-title":"Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2023.02.151_bb0195","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00000542-198003000-00008","article-title":"Pharmacology of ketamine isomers in surgical patients","volume":"52","author":"White","year":"1980","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jad.2023.02.151_bb0200","series-title":"Comparative Pharmacology of the Ketamine Studies in Volunteers","first-page":"197","author":"White","year":"1985"},{"key":"10.1016\/j.jad.2023.02.151_bb0205","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41386-018-0084-y","article-title":"(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice","volume":"43","author":"Yamaguchi","year":"2018","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.jad.2023.02.151_bb0210","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1007\/s00213-016-4399-2","article-title":"Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression","volume":"233","author":"Yang","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2023.02.151_bb0215","doi-asserted-by":"crossref","first-page":"e632","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2023.02.151_bb0220","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.psychres.2016.03.034","article-title":"Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine","volume":"239","author":"Yang","year":"2016","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2023.02.151_bb0225","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.biopsych.2016.12.020","article-title":"(R)-ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine","volume":"82","author":"Yang","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2023.02.151_bb0230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s44192-022-00012-3","article-title":"Ketamine treatment for depression: a review","volume":"2","author":"Yavi","year":"2022","journal-title":"Discov. Ment. Health"},{"key":"10.1016\/j.jad.2023.02.151_bb0235","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jad.2023.02.151_bb0240","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1111\/bph.14683","article-title":"(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses","volume":"176","author":"Zanos","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jad.2023.02.151_bb0245","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","article-title":"R(\u2212)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine","volume":"116","author":"Zhang","year":"2014","journal-title":"Pharmacol. Biochem. Behav."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723003233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723003233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T03:43:11Z","timestamp":1759030991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032723003233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":50,"alternative-id":["S0165032723003233"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2023.02.151","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2023.02.151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}